YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
HKD 11.9
(1.02%)
HKD 11.9
(1.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.99 Billion CNY | 2501.23% |
| 2022 | 76.6 Million CNY | 113.04% |
| 2021 | -587.64 Million CNY | -170.0% |
| 2020 | 839.45 Million CNY | -56.25% |
| 2019 | 1.91 Billion CNY | 103.57% |
| 2018 | 942.53 Million CNY | 45.66% |
| 2017 | 647.1 Million CNY | 70.02% |
| 2016 | 380.59 Million CNY | 43.22% |
| 2015 | 265.75 Million CNY | 96.35% |
| 2014 | 135.34 Million CNY | 134.16% |
| 2013 | 57.8 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 684.73 Million CNY | -28.91% |
| 2023 Q2 | 1.02 Billion CNY | 841.03% |
| 2023 FY | 1.99 Billion CNY | 2501.23% |
| 2023 Q4 | 963.12 Million CNY | -6.45% |
| 2022 Q4 | 109.4 Million CNY | 433.56% |
| 2022 FY | 76.6 Million CNY | 113.04% |
| 2022 Q2 | -32.79 Million CNY | 59.32% |
| 2021 FY | -587.64 Million CNY | -170.0% |
| 2021 Q2 | -507.02 Million CNY | -328.45% |
| 2021 Q4 | -80.62 Million CNY | 84.1% |
| 2020 Q2 | 617.5 Million CNY | -35.02% |
| 2020 FY | 839.45 Million CNY | -56.25% |
| 2020 Q4 | 221.94 Million CNY | -64.06% |
| 2019 FY | 1.91 Billion CNY | 103.57% |
| 2019 Q4 | 950.28 Million CNY | -1.87% |
| 2019 Q2 | 968.42 Million CNY | 214.43% |
| 2018 FY | 942.53 Million CNY | 45.66% |
| 2018 Q4 | 307.99 Million CNY | -51.46% |
| 2018 Q2 | 634.54 Million CNY | 83.8% |
| 2017 Q2 | 301.86 Million CNY | 82.27% |
| 2017 FY | 647.1 Million CNY | 70.02% |
| 2017 Q4 | 345.24 Million CNY | 14.37% |
| 2016 Q2 | 214.98 Million CNY | 91.09% |
| 2016 FY | 380.59 Million CNY | 43.22% |
| 2016 Q4 | 165.61 Million CNY | -22.97% |
| 2015 Q2 | 153.24 Million CNY | 187.6% |
| 2015 Q4 | 112.5 Million CNY | -26.59% |
| 2015 FY | 265.75 Million CNY | 96.35% |
| 2014 Q2 | 82.05 Million CNY | 142.52% |
| 2014 Q4 | 53.28 Million CNY | -35.06% |
| 2014 FY | 135.34 Million CNY | 134.16% |
| 2013 FY | 57.8 Million CNY | 0.0% |
| 2013 Q4 | 33.83 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -1797.033% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | -5.991% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 1322.851% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 13076.192% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 3880.712% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -11833.309% |
| Essex Bio-Technology Limited | 275.25 Million HKD | -623.907% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 7008.519% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 1978.399% |
| SSY Group Limited | 1.31 Billion HKD | -51.115% |
| JBM (Healthcare) Limited | 130.46 Million HKD | -1427.348% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | -646.391% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 48.301% |